{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:36:01Z","timestamp":1785245761136,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.psychres.2025.116929","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:17:55Z","timestamp":1766992675000},"page":"116929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)"],"prefix":"10.1016","volume":"357","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4027-5223","authenticated-orcid":false,"given":"Omer A.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Nestor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ishrat","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-2584","authenticated-orcid":false,"given":"Mark","family":"Sinyor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6642-6221","authenticated-orcid":false,"given":"Peter","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.psychres.2025.116929_bib0001","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","article-title":"Psychedelic medicine: safety and ethical concerns","volume":"7","author":"Anderson","year":"2020","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.psychres.2025.116929_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2025.111461","article-title":"An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: insights, limitations and future directions","author":"Askariyan","year":"2025","journal-title":"Progres. Neuro-Psychopharmacol. Biol. Psychiatr."},{"issue":"6","key":"10.1016\/j.psychres.2025.116929_bib0003","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00213-021-06049-6","article-title":"Assessing the risk\u2013benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research","volume":"239","author":"Bender","year":"2022","journal-title":"Psychopharmacology."},{"issue":"6","key":"10.1016\/j.psychres.2025.116929_bib0004","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12012-019-09526-9","article-title":"MDMA induced cardio-toxicity and pathological myocardial effects: a systematic review of experimental data and autopsy findings","volume":"19","author":"Bonsignore","year":"2019","journal-title":"Cardiovasc. Toxicol."},{"issue":"3","key":"10.1016\/j.psychres.2025.116929_bib0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ajmg.a.30441","article-title":"Fibular aplasia, tibial campomelia, and oligosyndactyly in a male newborn infant: a case report and review of the literature","volume":"134","author":"Courtens","year":"2005","journal-title":"Ameri. J. Med. Genetics Part A"},{"key":"10.1016\/j.psychres.2025.116929_bib0006","doi-asserted-by":"crossref","unstructured":"Courtney, Y.E., Anderson, J.M., Lagares-Linares, C., Wenthur, C.J., & Lehtinen, M.K. (2025). Gestational Psychedelic Exposure Disrupts Brain Development and Offspring Behavior in Mice. bioRxiv, 2025-09.","DOI":"10.1101\/2025.09.30.677638"},{"key":"10.1016\/j.psychres.2025.116929_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116622","article-title":"Efficacy and safety of LSD in the treatment of mental and substance use disorders: a systematic review of randomized controlled trials","author":"Fernandes-Nascimento","year":"2025","journal-title":"Psychiatry Res."},{"issue":"8","key":"10.1016\/j.psychres.2025.116929_bib0008","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.euroneuro.2017.06.004","article-title":"DSM-5 cannabis use disorder, substance use and DSM-5 specific substance-use disorders: evaluating comorbidity in a population-based sample","volume":"27","author":"Hayley","year":"2017","journal-title":"Euro. Neuropsychopharmacol."},{"issue":"7577","key":"10.1016\/j.psychres.2025.116929_bib0009","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(68)91569-9","article-title":"Lysergic-acid-diethylamide and cannabis as possible teratogens in man","volume":"292","author":"Hecht","year":"1968","journal-title":"The Lancet"},{"key":"10.1016\/j.psychres.2025.116929_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2024.2546","article-title":"Adverse events in studies of classic psychedelics: a systematic review and meta-analysis","author":"Hinkle","year":"2024","journal-title":"JAMA Psychiatr."},{"issue":"4","key":"10.1016\/j.psychres.2025.116929_bib0011","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/09540261.2018.1509544","article-title":"Psychiatry might need some psychedelic therapy","volume":"30","author":"Johnson","year":"2018","journal-title":"Int. Rev. Psychiatr."},{"issue":"1","key":"10.1016\/j.psychres.2025.116929_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-14809-3","article-title":"Associations between classic psychedelics and nicotine dependence in a nationally representative sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.psychres.2025.116929_bib0013","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1016\/j.cub.2021.12.009","article-title":"Psychedelics","volume":"32","author":"Kelmendi","year":"2022","journal-title":"Current Biol."},{"issue":"12","key":"10.1016\/j.psychres.2025.116929_bib0014","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1111\/add.16259","article-title":"Hallucinogen use among young adults ages 19\u201330 in the United States: changes from 2018 to 2021","volume":"118","author":"Keyes","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.psychres.2025.116929_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108715","article-title":"LSD use in the United States: trends, correlates, and a typology of us","volume":"223","author":"Killion","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.psychres.2025.116929_bib0016","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41398-024-03116-2","article-title":"Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects","volume":"14","author":"Klaiber","year":"2024","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2025.116929_bib0017","article-title":"A global population-based study on the association between ketamine and esketamine with suicidality using WHO VigiBase","volume":"86","author":"Kwan","year":"2025","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116929_bib0018","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jad.2024.07.128","article-title":"A replication study using the World Health Organization pharmacovigilance database (VigiBase\u00ae) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists","volume":"363","author":"Kwan","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.psychres.2025.116929_bib0019","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/02698811241292956","article-title":"Co-use of psychedelics with other substances: findings from the global psychedelic survey","volume":"39","author":"Lake","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116929_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2020.106479","article-title":"What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis","volume":"109","author":"Leung","year":"2020","journal-title":"Addict. Behav."},{"key":"10.1016\/j.psychres.2025.116929_bib0021","article-title":"Characteristic analysis of adverse reactions of five anti-tnf\u0251 agents: a descriptive analysis from WHO-VigiAccess","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2025.116929_bib0022","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00213-021-05876-x","article-title":"Serotonin toxicity of serotonergic psychedelics","volume":"239","author":"Malcolm","year":"2022","journal-title":"Psychopharmacology."},{"issue":"4","key":"10.1016\/j.psychres.2025.116929_bib54","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2853","article-title":"Psilocybin dispensaries and online health claims in Canada","volume":"8","author":"Matsukubo","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.psychres.2025.116929_bib0023","first-page":"385","article-title":"Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis","author":"Metaxa","year":"2024","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.psychres.2025.116929_bib0024","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.psychres.2025.116929_bib0025","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.psychres.2025.116929_bib0026","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatr."},{"issue":"6","key":"10.1016\/j.psychres.2025.116929_bib0027","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00213-022-06066-z","article-title":"Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants","volume":"239","author":"M\u00fcller","year":"2022","journal-title":"Psychopharmacology."},{"key":"10.1016\/j.psychres.2025.116929_bib0028","first-page":"1","article-title":"Cardiovascular effects and safety of classic psychedelics","author":"Nahlawi","year":"2025","journal-title":"Nat. Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.psychres.2025.116929_bib0029","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.psychres.2025.116929_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/20503245251380511","article-title":"A lexicon for psychedelic research and treatment","volume":"11","author":"Nutt","year":"2025","journal-title":"Drug Sci. Policy. Law"},{"issue":"9752","key":"10.1016\/j.psychres.2025.116929_bib0031","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"The Lancet"},{"key":"10.1016\/j.psychres.2025.116929_bib0032","series-title":"Proceedings of the 2024 CHI Conference on Human Factors in Computing Systems","first-page":"1","article-title":"Quantifying the Pollan effect: investigating the impact of emerging psychiatric interventions on online mental health discourse","author":"Pendse","year":"2024"},{"issue":"1","key":"10.1016\/j.psychres.2025.116929_bib0033","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s42238-024-00235-x","article-title":"Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using mixed methods","volume":"6","author":"Piercey","year":"2024","journal-title":"J. Cannabis. Res."},{"key":"10.1016\/j.psychres.2025.116929_bib0034","unstructured":"Pollan, M. (2015). The trip treatment. The New Yorker, 9."},{"key":"10.1016\/j.psychres.2025.116929_bib0035","first-page":"1","article-title":"Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases","author":"Rabbani","year":"2024","journal-title":"Expert. Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.psychres.2025.116929_bib0036","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Ameri. J. Psychiatr."},{"issue":"9","key":"10.1016\/j.psychres.2025.116929_bib0037","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/0269881120936508","article-title":"Perceived harm, motivations for use and subjective experiences of recreational psychedelic \u2018magic\u2019mushroom use","volume":"34","author":"Roberts","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116929_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115880","article-title":"Safety and risk assessment of psychedelic psychotherapy: a meta-analysis and systematic review","volume":"335","author":"Romeo","year":"2024","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.psychres.2025.116929_bib0039","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/02698811231225609","article-title":"Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: comparison to known cardiotoxins","volume":"38","author":"Rouaud","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2025.116929_bib0040","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/02698811211069100","article-title":"Adverse effects of psychedelics: from anecdotes and misinformation to systematic science","volume":"36","author":"Schlag","year":"2022","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116929_bib0041","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/psymed.2024.0033","article-title":"Exploring psychedelics for unmet needs in women\u2019s reproductive health","volume":"3","author":"Shoar","year":"2025","journal-title":"Psychedelic Medicine"},{"key":"10.1016\/j.psychres.2025.116929_bib0042","doi-asserted-by":"crossref","unstructured":"Siff, S. (2015). Acid hype: American news Media and the Psychedelic Experience. University of Illinois Press.","DOI":"10.5406\/illinois\/9780252039195.001.0001"},{"key":"10.1016\/j.psychres.2025.116929_bib0043","unstructured":"Sutherland, R., Chandrasena, U., Karlsson, A., Uporova, J., Tayeb, H., Price, O., & Peacock, A. (2024). Australian Drug Trends 2024: Key Findings From the National Ecstasy and Related Drugs Reporting System (EDRS) Interview."},{"key":"10.1016\/j.psychres.2025.116929_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2025.111419","article-title":"Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder (MDD) patients: a systematic review of early-phase clinical trials","author":"Swieczkowski","year":"2025","journal-title":"Progres. Neuro-Psychopharmacol. Biol. Psychiatr."},{"issue":"1","key":"10.1016\/j.psychres.2025.116929_bib0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s44184-023-00044-9","article-title":"Managing expectations with psychedelic microdosing","volume":"2","author":"Syed","year":"2023","journal-title":"NPJ Mental Health Res."},{"issue":"10","key":"10.1016\/j.psychres.2025.116929_bib0046","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.tips.2023.08.001","article-title":"A perspective on psychedelic teratogenicity: the utility of zebrafish models","volume":"44","author":"Syed","year":"2023","journal-title":"Trends. Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.psychres.2025.116929_bib0047","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/02698811231190865","article-title":"The risk of chronic psychedelic and MDMA microdosing for valvular heart disease","volume":"37","author":"Tagen","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116929_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.675768","article-title":"On perception and consciousness in HPPD: a systematic review","volume":"15","author":"Vis","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.psychres.2025.116929_bib0049","article-title":"The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116929_bib0050","doi-asserted-by":"crossref","unstructured":"Williams, M.L., Hitchcock, K., Miller, A.H., & Beck, S.A. (2025). Eligibility For Psychedelic therapy: Clinical trial Medical Exclusion Criteria and Their Implications For Hospital Practice. General Hospital Psychiatry.","DOI":"10.1016\/j.genhosppsych.2025.12.009"},{"key":"10.1016\/j.psychres.2025.116929_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108071","article-title":"Trends in LSD use among US adults: 2015\u20132018","volume":"212","author":"Yockey","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.psychres.2025.116929_bib0052","article-title":"Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases","volume":"12","author":"Zhao","year":"2025","journal-title":"Front. Med."},{"issue":"7525","key":"10.1016\/j.psychres.2025.116929_bib0053","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(67)90339-X","article-title":"Is lysergic-acid diethylamide a teratogen?","volume":"290","author":"Zellweger","year":"1967","journal-title":"The Lancet"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125005748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125005748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:06:40Z","timestamp":1769490400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178125005748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"alternative-id":["S0165178125005748"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116929","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116929"}}